Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology

Research output: Contribution to journalArticlepeer-review

Standard

Evidence-based guidelines for the pharmacological treatment of schizophrenia : updated recommendations from the British Association for Psychopharmacology. / Barnes, Thomas Re; Drake, Richard; Paton, Carol; Cooper, Stephen; Deakin, J. F.W.; Ferrier, Nicol; Lewis, Shon; Joyce, Eileen M; Upthegrove, Rachel; Yung, Alison.

In: Journal of Psychopharmacology, 01.01.2020.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Barnes, Thomas Re ; Drake, Richard ; Paton, Carol ; Cooper, Stephen ; Deakin, J. F.W. ; Ferrier, Nicol ; Lewis, Shon ; Joyce, Eileen M ; Upthegrove, Rachel ; Yung, Alison. / Evidence-based guidelines for the pharmacological treatment of schizophrenia : updated recommendations from the British Association for Psychopharmacology. In: Journal of Psychopharmacology. 2020.

Bibtex

@article{eb7d8f0f65e24f45b5ddae1886d79991,
title = "Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology",
abstract = "These updated guidelines from the British Association for Psychopharmacology replace the original version published in 2011. They address the scope and targets of pharmacological treatment for schizophrenia. A consensus meeting was held in 2017, involving experts in schizophrenia and its treatment. They were asked to review key areas and consider the strength of the evidence on the risk-benefit balance of pharmacological interventions and the clinical implications, with an emphasis on meta-analyses, systematic reviews and randomised controlled trials where available, plus updates on current clinical practice. The guidelines cover the pharmacological management and treatment of schizophrenia across the various stages of the illness, including first-episode, relapse prevention, and illness that has proved refractory to standard treatment. It is hoped that the practice recommendations presented will support clinical decision making for practitioners, serve as a source of information for patients and carers, and inform quality improvement.",
keywords = "Guideline, schizophrenia, psychopharmacology",
author = "Barnes, {Thomas Re} and Richard Drake and Carol Paton and Stephen Cooper and Deakin, {J. F.W.} and Nicol Ferrier and Shon Lewis and Joyce, {Eileen M} and Rachel Upthegrove and Alison Yung",
year = "2020",
month = jan,
day = "1",
doi = "10.1177%2F1741143219888738",
language = "English",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications",

}

RIS

TY - JOUR

T1 - Evidence-based guidelines for the pharmacological treatment of schizophrenia

T2 - updated recommendations from the British Association for Psychopharmacology

AU - Barnes, Thomas Re

AU - Drake, Richard

AU - Paton, Carol

AU - Cooper, Stephen

AU - Deakin, J. F.W.

AU - Ferrier, Nicol

AU - Lewis, Shon

AU - Joyce, Eileen M

AU - Upthegrove, Rachel

AU - Yung, Alison

PY - 2020/1/1

Y1 - 2020/1/1

N2 - These updated guidelines from the British Association for Psychopharmacology replace the original version published in 2011. They address the scope and targets of pharmacological treatment for schizophrenia. A consensus meeting was held in 2017, involving experts in schizophrenia and its treatment. They were asked to review key areas and consider the strength of the evidence on the risk-benefit balance of pharmacological interventions and the clinical implications, with an emphasis on meta-analyses, systematic reviews and randomised controlled trials where available, plus updates on current clinical practice. The guidelines cover the pharmacological management and treatment of schizophrenia across the various stages of the illness, including first-episode, relapse prevention, and illness that has proved refractory to standard treatment. It is hoped that the practice recommendations presented will support clinical decision making for practitioners, serve as a source of information for patients and carers, and inform quality improvement.

AB - These updated guidelines from the British Association for Psychopharmacology replace the original version published in 2011. They address the scope and targets of pharmacological treatment for schizophrenia. A consensus meeting was held in 2017, involving experts in schizophrenia and its treatment. They were asked to review key areas and consider the strength of the evidence on the risk-benefit balance of pharmacological interventions and the clinical implications, with an emphasis on meta-analyses, systematic reviews and randomised controlled trials where available, plus updates on current clinical practice. The guidelines cover the pharmacological management and treatment of schizophrenia across the various stages of the illness, including first-episode, relapse prevention, and illness that has proved refractory to standard treatment. It is hoped that the practice recommendations presented will support clinical decision making for practitioners, serve as a source of information for patients and carers, and inform quality improvement.

KW - Guideline

KW - schizophrenia

KW - psychopharmacology

U2 - 10.1177%2F1741143219888738

DO - 10.1177%2F1741143219888738

M3 - Article

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

ER -